Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose Escalation and Dose Expansion Study of WJ01024 to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy for Patients With Advanced Cancer

Next Previous
X
Search
Trial Profile

A Dose Escalation and Dose Expansion Study of WJ01024 to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy for Patients With Advanced Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs WJ 01024 (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Suzhou Junjing BioSciences

    • Most Recent Events

    • 24 May 2024 Treatments section is updated to decrease the doses of 100, 120, 140 and 160 mg twice a week to 60, 80, 50 and 40 mg once per week respectively.
    • 24 May 2024 Planned number of patients changed from 108 to 66.
    • 24 May 2024 Planned End Date changed from 30 Apr 2024 to 30 Apr 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top